Skip Navigation


JAC Advance Access originally published online on November 18, 2002
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
50/6/1075    most recent
dkg003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chiu, L. M.
Right arrow Articles by Amsden, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chiu, L. M.
Right arrow Articles by Amsden, G. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2002) 50, 1075-1079
© 2002 The British Society for Antimicrobial Chemotherapy

Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers

L. M. Chiu, A. M. Menhinick, P. W. Johnson and G. W. Amsden*

Clinical Pharmacology Research Center, Bassett Healthcare, One Atwell Road, Cooperstown, NY 13326, USA

Received 5 July 2002; returned 8 August 2002; revised 18 September 2002; accepted 20 September 2002

This study was conducted to identify whether or not a pharmacokinetic interaction existed when azithromycin and ceftriaxone were administered concurrently. This randomized, open-label, three-way crossover study in 12 healthy volunteers characterized the plasma pharmacokinetic parameter profiles of both drugs, as well as the white blood cell uptake and exposure to azithromycin, when the drugs were administered alone and together. The plasma pharmacokinetic parameters for azithromycin and ceftriaxone did not differ significantly either after a single dose or at steady state when the two were co-administered as opposed to being administered alone. Moreover, the neutrophil and monocyte/lymphocyte peak azithromycin concentrations and sampling period exposures also did not differ significantly between the study arm and the control arm. This study confirms that there is no interaction between azithromycin and ceftriaxone when they are administered concurrently.

Keywords: azithromycin, ceftriaxone, pharmacokinetics

* Corresponding author. Tel: +1-607-547-3399; Fax: +1-607-547-6914; E-mail: guy.amsden{at}bassett.org


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
D. Sevillano, L. Alou, L. Aguilar, O. Echevarria, M.-J. Gimenez, and J. Prieto
Azithromycin iv pharmacodynamic parameters predicting Streptococcus pneumoniae killing in epithelial lining fluid versus serum: an in vitro pharmacodynamic simulation
J. Antimicrob. Chemother., June 1, 2006; 57(6): 1128 - 1133.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. S. Burgess and C. R. Frei
Comparison of {beta}-lactam regimens for the treatment of Gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics
J. Antimicrob. Chemother., November 1, 2005; 56(5): 893 - 898.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.